Volume | 3,566,163 |
|
|||||
News | - | ||||||
Day High | 16.11 | Low High |
|||||
Day Low | 15.755 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ImmunoGen Inc | IMGN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
16.03 | 15.755 | 16.11 | 15.87 | 16.00 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
31,571 | 3,566,163 | $ 15.93 | $ 56,812,578 | - | 3.605 - 20.69 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:31:46 | priorref | 9,683 | $ 15.87 | USD |
ImmunoGen (IMGN) Options Flow Summary
ImmunoGen Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.95B | 248.94M | - | 108.78M | -222.93M | -0.90 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ImmunoGen News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMGN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 14.97 | 16.11 | 14.47 | 15.19 | 2,898,228 | 0.90 | 6.01% |
1 Month | 16.04 | 16.435 | 14.41 | 15.47 | 3,374,457 | -0.17 | -1.06% |
3 Months | 18.64 | 20.69 | 13.83 | 16.47 | 4,175,673 | -2.77 | -14.86% |
6 Months | 3.71 | 20.69 | 3.66 | 14.12 | 6,061,464 | 12.16 | 327.76% |
1 Year | 4.68 | 20.69 | 3.605 | 10.64 | 4,806,316 | 11.19 | 239.1% |
3 Years | 3.53 | 20.69 | 3.095 | 8.06 | 3,481,966 | 12.34 | 349.58% |
5 Years | 9.50 | 20.69 | 1.65 | 6.69 | 3,132,668 | 6.37 | 67.05% |
ImmunoGen Description
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies. |